Table 3.

The role of USP11 in cancer management.

Cancer types	Substrates	Effects	Role of USP11	Reference
Colorectal cancer	PPP1CA	USP11 facilitates growth and metastasis of colorectal cancer	Promoters	[78]
	IGF2BP3	USP11 promotes colorectal cancer proliferation and metastasis	Promoters	[79]
	VCP	USP11 induce resistance to 5-Fluorouracil in colorectal cancer via activating autophagy	Promoters	[34]
	P21	USP11 inhibits growth and metastasis of colorectal cancer	Inhibitor	[32]
	Cyclin D1	Circ-DDCK1 regulates USP11 via miR-132-3P to promote colorectal cancer progression	Promoters	[38]
Lung squamous cell carcinoma	ARID1A	Trim32/USP11 regulates ARID1A stability and the occurrence/inhibition of lung squamous cell carcinoma	Inhibitor	[85]
Breast cancer	PTEN	USP11 regulates PTEN to stabilize tumor suppression	Inhibitor	[92]
	XIAP	USP11 regulates XIAP stability to facilitate tumorigenesis of breast cancer	Promoters	[93]
	TGFBR2	USP11 triggers epithelial-to-mesenchymal transition and promotes invasion and proliferation of breast cancer	Promoters	[94]
	ERα/Cyclin D1	USP11 is identified as a novel transcriptional regulator of ERα in breast cancer	Promoters	[36]
	Non	USP11 as a predictive and prognostic factor following neoadjuvant therapy in breast cancer	Biomarker	[95]
Esophageal squamous cell carcinoma	ARID1A	Trim32/USP11 regulates ARID1A stability and the occurrence/inhibition of esophageal squamous cell carcinoma	Inhibitor	[85]
Ovarian cancer	BIP	USP11 promotes ovarian cancer chemoresistance of carboplatin	Promoters	[28]
	Snail	USP11 promotes epithelial-to-mesenchymal transition of ovarian cancer	Promoters	[99]
Prostate cancer	PTEN	USP11 regulates PTEN to stabilize tumor suppression	Inhibitor	[92]
Renal clear cell adenocarcinoma	VGLL4	USP11 functions as a tumor suppressor through stabilizing VGLL4	Inhibitor	[100]
Hepatocellular carcinoma	NF90	USP11 regulates NF90 to promote proliferation and metastasis in hepatocellular carcinoma	Promoters	[88]
	KLF4	USP11 facilitates the progression and sorafenib chemoresistance of hepatocellular carcinoma	Promoters	[30]
	E2F1	E2F1/USP11 positive feedback loop promotes hepatocellular carcinoma metastasis and inhibits autophagy by activating ERK/mTOR pathway	Promoters	[87]
	Non	USP11 serves as a marker of poor prognosis and promotes metastasis in hepatocellular carcinoma	Biomarker	[86]
Gastric cancer	RhoA	USP11 facilitates chemotherapy resistance of gastric cancer via RhoA and Ras-mediated signaling pathway	Promoters	[35]
Pancreatic cancer	BRCA2	Mitoxantrone targets USP11 and is a potent inhibitor of pancreatic cancer cell survival	Promoters	[89]
Melanoma	NONO	USP11 stabilizes NONO and promotes the proliferation of melanoma	Promoters	[107]
Skin squamous cell carcinoma	VCP/P97	USP11 is declined in skin squamous cell carcinoma and serve a potential tumor suppressor	Biomarker	[21]
Glioma	PML	USP11 stabilizes PML stability to control Notch-induced malignancy in brain tumors	Inhibitor	[33]
Non-small cell lung cancer	P21	USP11 inhibits the proliferation of non-small cell lung cancer dependent on p21 activity	Inhibitor	[32]
Osteosarcoma	RAE	USP11 promotes the proliferation in osteosarcoma U2OS cell	Promoters	[105]
	Non	USP11 as a survival-related differentially expressed gene	Biomarker	[111]
Cervical cancer	HPV-16E7	USP11 stabilizes HPV-16E7 to promote progression of cervical cancer	Promoters	[104]
Lymphoma	eIF4B	Activated USP11 promotes lymphomagenesis via stabilizing and deubiquitinating eIF4B	Promoters	[37]